EMEA-002726-PIP01-19-M01

Table of contents

Key facts

Active substance
Garadacimab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0274/2021
PIP number
EMEA-002726-PIP01-19-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Prevention of hereditary angioedema attacks
Route(s) of administration
Subcutaneous use
Contact for public enquiries
CSL Behring GmbH
E-mail: EU-CSLBehring@cslbehring.com
Tel: +41 795386261
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating